

Medically Assisted Reproduction (MAR) in the Context of the COVID-19 Pandemic

Marcos Horton*

Pregna Reproductive Center, Buenos Aires, Argentina

Abstract

The current COVID-19 pandemic poses a unique challenge for the provision of standard healthcare services. Medically Assisted Reproduction (MAR) includes interventions aimed to treat infertility, or provide services to single women or same sex couples wishing to conceive. The right to a family is a human right, as stated by the World Health Organization (WHO), and infertility is considered a disease, often time-sensitive; thus, delaying timely treatment can

We assessed the impact of the pandemic on fertility treatment from a global perspective, describing the timeline commencing MAR care in a safe environment. We describe the safety protocol put in place in our clinic, its results, and neonatal health.

Keywords: Medically assisted reproduction; MAR; COVID-19; SARS-CoV-2; IVF; Pandemic; ART services; Coronavirus disease 2019

Abstract

The COVID-19 pandemic has rapidly unfolded since its outbreak

*Corresponding author: Marcos Horton, Pregna Reproductive Center, Buenos Aires, Argentina, Tel: (+54) 114-831-5900; E-mail: mhorton@pregna.com.ar

Received: October 21, 2020; Accepted: November 04, 2020; Published: November 11, 2020

Citation: Horton M (2020) Medically Assisted Reproduction (MAR) in the Context of the COVID-19 Pandemic. Diagn Pathol Open S1: 001.

Copyright: © 2020 Horton M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

MAR is mandatory, or these procedures are not considered “essential” medical services.

The first reaction of the MAR community to the pandemic was a “precautionary approach” taking into consideration the lack of knowledge about the effects of the SARS-CoV-2 virus on the reproductive process. No data was available on the presence of the virus in human gametes, its impact in early pregnancy, vertical transmission during the second and third trimester, obstetrical or neonatal morbidity/mortality, or effects on lactation. Some of the initial guidance was also influenced by information on the significant obstetrical impact of two previous coronavirus outbreaks (SARS-CoV and MERS), which showed

followed guidelines and has been largely responsive to public health and individual patient concerns [15].

Along with the evolving pandemic, various organizations have been reporting and monitoring their results and opening registries on the prognosis and evolution of pregnancies affected by COVID-19. ESHRE is collecting data on a simple online survey in their webpage, that offers case-by-case reporting on outcomes of MAR pregnancies with a COVID-19 diagnosis confirmed [10], and the upcoming 9th edition of IFFS Surveillance, a triennial survey reporting on global MAR activity, policies and regulations will include data on activity during the pandemic (Steve Ory, personal communication).

In the meantime, a growing body of evidence in the literature is showing reassuring data on the maternal and neonatal outcome of pregnancies affected by COVID-19, with isolated cases of vertical transmission limited to severely ill mothers, with an average pooled incidence estimated in 16 per 1000 newborns [16]. A recent “living” systematic review and meta-analysis scheduled to continuously monitor and follow up COVID-19 pregnancies, reported results on 11,432 pregnant women from 77 studies spanning from December 2019 through June 2020 [17]. The paper showed that pregnant women with COVID-19 infection are less likely to manifest symptoms of fever and myalgia and are more likely to present preterm birth and an increase in neonatal admissions. Risk factors for severe COVID in pregnancy included increase maternal age, high body mass index, and pre-existing co-morbidities.

Currently, MAR centers worldwide are following guidelines from the constantly updated statements of appointed task forces from the Scientific Societies. Overall, these emphasize on general recommendations of personal hygiene, social distancing and face masking, but especially triage, testing protocols and indications, and personnel reorganization, plus telemedicine and emergency protocols.

At our clinic (unpublished data), an infectious disease committee was established, and developed a comprehensive program including training, reading materials and infographic tools for personnel, and reorganized everyday work to adapt to the current situation. All staff at the clinic (medical and non-medical) is triaged daily through a digital questionnaire and an official app as well, and follow similar precautions, with organization of working teams ready for replacement of sick individuals. Consultations are preferentially managed through telemedicine platforms, especially for initial consultations, review of reports and medical studies, or second opinions. If done in-person, consultations and ultrasound monitoring are now done using face masks, and eye protection through goggles or a face shield. Consultations are scheduled to avoid waiting room overcrowding, and must ideally have a 15 minute limit, partners are not allowed to attend, and every patient entering the clinic is triaged through a digital questionnaire received by mail upon confirmation of the scheduled visit. Once in the clinic, the triage is reviewed and a temperature check is done. In this way, after six months working under this protocol, we had 9 contagions (Figure 1a), all related to their households and close relatives. The pattern followed the dynamics of the epidemiological curve in our city (Figure 1b) have avoided in-house outbreaks that would be significant challenges remain in our knowledge of COVID-19 disease and its consequences in reproduction, MAR treatments, and pregnancy thereafter. Obstetrical and neonatal prognosis is reassuring based on the current published data, with a slight increase in preterm birth and neonatal admissions and an extremely low vertical transmission rate, limited to severe cases.

A prudent approach from the doctor and the clinic should be in place, including comprehensive discussion with patients and prospective parents on the risks and benefits of getting pregnant during the pandemic, offering alternative treatments including gamete or embryo cryopreservation, and in eligible cases, postponing treatment.

However, family foundation is a human right and infertility is a disease, very often time-sensitive, and delaying treatment under the argument of a pandemic is not justified by current evidence. It has decimated our staff and increased the risk of propagation to patients.

4. Boivin J, Bunting L, Collins JA, Nygren KG (2007) International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod 22: 1506-1512.
5. World Health Organization (2020) Infertility.
6. Zegers-Hochschild F, DicXochschilO Estimates of m Reprod 22: A36.311 1-99(i)T.D[Horton

1. Coronavirus Resource Center COVID-19 (2020) Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University.
2. Ü[•^}äæ" {ÁŠí(ÇEG@V@^Á~ }c[|áá c[|E@^Á]æ}á^ {i&q;Á^ ^&c•Á []Á]æç^}c•Á , á@ [~ ç COVID-19. N Engl J Med 382: 24.
3. Zegers-Hochschild F, Adamson GD, Dyer S, Racowsky C, De Mouzon J, et al. (2017) The international glossary on infertility and fertility care, 2017. Hum Reprod 32: 1786-1801.

12. Alviggi C, Esteves SC, Orvieto R, Conforti A, La Marca A, et al. (2020) COVID-19 and assisted reproductive technology services: Repercussions for patients and proposal for individualized clinical management. *Reprod Biol Endocrinol* 18: 45.
13. Vermeulen N, Ata B, Gianaroli L, Lundin K, Mocanu E, et al. (2020) A picture of medically assisted reproduction activities during the COVID-19 pandemic in Europe. *Hum Reprod Open* 2020: hoaa035.
14. Gianaroli L, Ata B, Lundin K, Rautakallio-Hokkanen S, Tapanainen JS, et al. (2020) The calm after the storm: Re-starting ART treatments safely in the wake of the COVID-19 pandemic. *Hum Reprod*.
15. Ory S, Miller K, Horton M, Giudice L (2020) The global impact of COVID-19 on infertility services. *Glob Reprod Health* 2: 43.
16. Goh XL, Low YF, Ng CH, Amin Z, Ng YP (2020) Incidence of SARS-CoV-2 vertical transmission: A meta analysis. *Arch Dis Child Fetal Neonatal Ed* 2020: 319791.
17. Allotey J, Stallings E, Bonet M, Yap M, Chatterjee S, et al. (2020) Clinical manifestations, risk factors, and maternal and perinatal outcomes of coronavirus disease 2019 in pregnancy: Living systematic review and meta-analysis. *BMJ* 370: m3320.